Premier Partners — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
Celltrio manufactures robotic automation systems for the life sciences industry, with patented technology for biobanking and cell culturing automation.
BiotechHardwareHealthtechRoboticsFremont, US
Charlie Duncheon(CEO & Cofounder)Jin-Oh Kim(CTO & Cofounder)Raphael Kim(VP, Software Engineering & Cofounder)inJeff Baird(Chief Operations Officer)inChau Chavez(CFO)
BoardMinbeom Kim(Director)
Co-investorsAsia2G Capital
Korean aesthetic-medicine platform, operated by Healing Paper, connecting users with clinics for treatment information and bookings.
Co-investorsAtinum Investment Co. Ltd.Kiwoom InvestmentKT investment Inc.KT Strategic Investment Fund 4Aju IB InvestmentDSC Investment+4 more
Prazer Therapeutics develops therapeutics using Targeted Protein Degradation (TPD) technology, including its SPiDEM platform, in which small molecules selectively bind pathological proteins and activate the ubiquitin-proteasome system for their elimination.
BiotechDeep TechSeoul, KR
Co-investorsKiwoom InvestmentCompany K PartnersSmilegate Investment
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.



